Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
15:29:36 EDT Sun 05 May 2024
Enter Symbol
or Name
USA
CA



Q:SGMO - SANGAMO THERAPEUTICS INC - http://www.sangamo.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
SGMO - Q2.50.5074·0.575.00.5558+0.03386.51,184.55322,7310.522  0.5598  0.521.67  0.291119:49:57May 0215 min RT 2¢

Recent Trades - Last 10 of 2731
Time ETExPriceChangeVolume
19:49:57Q0.5530.0315
19:34:32Q0.530.0081
18:57:25Q0.530.0085,000
18:50:54Q0.5530.0313
18:41:47Q0.550.02843
18:38:40Q0.5530.03144
18:38:07Q0.530.008200
18:05:37Q0.53730.01538
17:52:51Q0.53810.0161196
17:46:02Q0.550.028200

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-05-02 16:15U:SGMONews ReleaseSangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast
2024-04-22 16:35U:SGMONews ReleaseSangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
2024-03-22 08:05U:SGMONews ReleaseSangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
2024-03-13 08:05U:SGMONews ReleaseSangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
2024-03-13 08:01U:SGMONews ReleaseSangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs
2024-03-12 18:30U:SGMONews ReleaseSangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast
2024-02-12 08:05U:SGMONews ReleaseSangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease
2024-02-05 18:01U:SGMONews ReleaseSangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile
2023-11-01 16:01U:SGMONews ReleaseSangamo Therapeutics Announces Strategic Update and Reports Third Quarter 2023 Financial Results
2023-10-25 16:15U:SGMONews ReleaseSangamo Therapeutics Announces Third Quarter 2023 Conference Call and Webcast
2023-10-24 02:01U:SGMONews ReleaseSangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
2023-09-20 16:15U:SGMONews ReleaseSangamo Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit
2023-08-08 16:01U:SGMONews ReleaseSangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results
2023-08-01 16:15U:SGMONews ReleaseSangamo Therapeutics Announces Second Quarter 2023 Conference Call and Webcast
2023-07-20 08:05U:SGMONews ReleaseSangamo Therapeutics and Chroma Medicine Announce Option and License Agreement to Evaluate and Develop Zinc Finger Proteins for Epigenetic Editing
2023-07-17 08:05U:SGMONews ReleaseSangamo Therapeutics Announces Research Evaluation and Option Agreement With Prevail, a Wholly Owned Subsidiary of Lilly, for Novel Engineered Capsids
2023-06-29 08:05U:SGMONews ReleaseSangamo Therapeutics and Voyager Therapeutics Enter License Agreement for Epigenetic Regulation Treatment of Prion Disease
2023-05-22 08:05U:SGMONews ReleaseSangamo Therapeutics Receives U.S. FDA Fast Track Designation for Isaralgagene Civaparvovec for the Treatment of Fabry Disease
2023-05-16 08:00U:SGMONews ReleaseSangamo Therapeutics Announces Appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer